Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech Inc. (NYSE American: AIM) has been granted U.S. patent No. 12,102,649 for using Ampligen® to treat endometriosis, a condition affecting nearly 10% of reproductive-age women. The patent covers compositions and methods using AIM's double-stranded RNA products for treating endometriosis, including recurrent cases. It also includes options for co-administration with interferons.

Endometriosis, affecting approximately 6.5 million women in the U.S., causes severe pelvic pain and fertility issues. The patented treatment offers flexible administration options for patient-specific care. Dr. Robert Edwards, Chair of Ob/Gyn/RS at UPMC, noted that a medical therapy relieving symptoms and reducing inflammation would be a significant breakthrough. AIM's CEO, Thomas K. Equels, stated that this patent strengthens their intellectual property portfolio and expands their potential to provide life-changing therapies for women with endometriosis.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced a $1.26 million registered direct offering of common stock and a concurrent private placement of warrants. The company will sell 4,653,036 shares at $0.27 per share to a single institutional investor. Additionally, AIM will issue unregistered Class C and Class D warrants to purchase up to 4,653,036 shares each, with an exercise price of $0.28. The Class C warrants expire 18 months after the initial exercise date, while Class D warrants expire after 5 years. Maxim Group is acting as the sole placement agent. The offering is made under a shelf registration statement, and a prospectus supplement will be filed with the SEC.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced that its Chief Executive Officer, Thomas K. Equels, will participate in a Virtual Investor CEO Connect segment on Wednesday, October 2, 2024, at 4:00 PM ET. The event will feature a brief presentation by Mr. Equels, followed by an interactive Q&A session.

Investors and interested parties can submit questions live during the event or pre-submit them via email to AIM@jtcir.com. A live video webcast of the presentation will be available on the Events page of the Company's website (aimimmuno.com). A webcast replay will be accessible for 90 days, starting two hours after the live presentation.

AIM ImmunoTech (NYSE American: AIM) reported positive preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi combination therapy for late-stage pancreatic cancer. The study showed stable disease in two out of three patients at 6 months in the first subject cohort. The combination therapy was generally well-tolerated with no severe adverse events. In the second cohort, two of three subjects also have stable disease, though not yet at the 6-month mark. Prof. Casper H.J. van Eijck noted improvements in quality of life and no toxicity, comparing favorably to typical disease progression rates. The data suggests Ampligen's potential synergy with checkpoint inhibitors for treating late-stage pancreatic cancer.

AIM ImmunoTech (NYSE American: AIM) has announced promising results from its AMP-518 Phase 2 clinical trial for Ampligen as a potential treatment for moderate-to-severe Post-COVID fatigue. The analysis showed that patients with Long COVID who received Ampligen were able to walk farther in a Six-Minute Walk Test (6MWT) compared to those who received a placebo.

Notably, subjects with a baseline 6MWT less than 205 meters showed significant improvement, with a mean increase of 139 meters compared to 91 meters in the placebo group. Based on these findings, AIM plans to focus future trials on patients with moderate or worse Long COVID-related fatigue. The company has also made key appointments to strengthen its medical team and research efforts in this area.

AIM ImmunoTech (NYSE American: AIM) announced the print publication of data analysis from a long-term Early Access Program studying Ampligen® (rintatolimod) for treating advanced pancreatic ductal adenocarcinoma (PDAC) in Clinical Cancer Research. The study, conducted at Erasmus University Medical Center, found that Ampligen enhances peripheral immune activity in pancreatic cancer patients, particularly involving type 1 conventional dendritic cells and T cells.

Key findings include:

• Increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes
• Decreased expression of immune checkpoints PD-L1 and PD-L2 post-Ampligen
• Potential for Ampligen to improve progression-free survival and overall survival

AIM ImmunoTech Inc. (NYSE American: AIM) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:

Financial Results:

• Cash, cash equivalents, and marketable securities: $10.1 million as of June 30, 2024
• R&D expenses: $1.1 million for Q2 2024, down from $3.0 million in Q2 2023
• G&A expenses: $2.6 million for Q2 2024, unchanged from Q2 2023
• Net loss: $1.8 million ($0.03 per share) for Q2 2024, compared to $4.9 million ($0.10 per share) in Q2 2023

Corporate Updates:

• New positive data on Ampligen's anti-tumor potential in melanoma treatment
• Publication of results in the peer-reviewed journal Vaccines
• Continued progress in Ampligen clinical development programs

AIM ImmunoTech Inc. (NYSE American: AIM) has announced a conference call and webcast to discuss its Q2 2024 operational and financial results on Friday, August 16, 2024, at 8:30 AM ET. The call will be hosted by CEO Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Investors can access the call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international), referencing the AIM ImmunoTech Conference Call. The webcast will be available on the company's website, aimimmuno.com, in the Investors section's Events page and will be archived for 90 days after the event.

AIM ImmunoTech Inc. (NYSE American: AIM) has released a new CEO Corner segment on its website. In this segment, CEO Thomas Equels discusses the positive data from the Phase 1 clinical trial that investigated an Ampligen-containing chemokine modulation therapy used in combination with the chemotherapy drug paclitaxel. The trial focused on the treatment of early stage, triple-negative breast cancer. This update provides investors with insights into the company's progress in developing potential cancer treatments and its ongoing clinical research efforts.